Subacute cardiotoxicity caused by anthracycline therapy in children: Can dexrazoxane prevent this effect?;Az antraciklinek kardiotoxikus hatásának kivédé se gyermekekben

Magyar Onkologia

Volumn 50, Issue 1, 2006, Pages 25-32

  Erlaky, Hajna ^a   Tóth, Kornélia ^a   Szabolcs, Judit ^a   Horváth, Erzsébet ^a   Kemény, Viktória ^a   Müller, Judit ^a   Csóka, Mónika ^a   Jókúti, László ^a   Erdélyi, Dániel ^a   Kovács, Gábor ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC ANTIBIOTIC; CARDIOTONIC AGENT; RAZOXANE;

ADOLESCENT; ARTICLE; CHEMICALLY INDUCED DISORDER; CHILD; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART; HEART LEFT VENTRICLE FUNCTION; HUMAN; MALE; PATHOPHYSIOLOGY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHY, DILATED; CARDIOTONIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HEART; HUMANS; MALE; RAZOXANE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 33747438927     PISSN: 00250244     EISSN: 20600399     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Ali MK, Ewer MS, Gibbs HR, et al. Late doxorubicinassociated cardiotoxicity in children. The possible role of intercurrant viral infection. Cancer 74:182-188, 1994
2. Burgert EO Jr, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup study IESS-II. J Clin Oncol 8:1514-1524, 1990
3. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup rhabdomyosarcoma study. J Clin Oncol 13:610-630, 1995
4. Della-Torre P, Podesta A, Imondi AR, et al. PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxic potential. Cancer Chemother Pharmacol 47:355-360, 2001
5. Dowd NP, Scully M, Adderley SR, et al. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 108:585-590, 2001
6. Fujimaki K, Maruta A, Yoshida M, et al. Severe cardiac toxicity in hematological stem cell transplantation: Predictive value of reduced left ventricular ejection fraction. Bone Marrow Transplant 27:307-310, 2001
7. Geidel S, Garn M, Gravinghoff L, et al. Cardiomyopathy after osteosarcoma-treatment: A contribution to the cardiotoxicity of adriamycin. Klin Padiatr 203:257-261, 1991
8. Greiner MA, Lipschultz SE. Epidemiology af anthracycline cardiotoxicity in children and adults. Semin Oncol 25(Suppl 10):72-85, 1998
9. Hasinoff BB, Hellmann K, Herman EH, et al. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 5:1-28, 1998
10. Hasinoff BB. Chemistry of dexrazoxane and analogues. Semin Oncol 25(Suppl 10):3-9, 1998
11. Hausdorf G, Mork G, Beron G, et al. Long-term doxorubicin cardiotoxicity in childhood: Noninvasive evaluation of the contractile state and diastolic filling. Br Heart J 60:309-315, 1988
12. Hauser M, Gibson BS, Wilson N. Diagnosis of anthracycline-induced late cardiomyopathy by exercisespiroergometry and stress-echocardiography. Eur J Pediatr 160:607-610, 2001
13. Hitchcock-Bryan S, Gelber R, Cassady JR, et al. The impact of induction anthracycline on long-term failurefree survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 14: 211-215, 1986
14. Iarussi D, Galderisi M, Ratti G. Left ventricular systolic and diastolic function after anthracycline chemotherapy in childhood. Clin Cardiol 24:663-669, 2001
15. Imondi AR. Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects. Semin Oncol 25(Suppl 10):22-30, 1998
16. Johnson GL, Moffert CB, Geil JD, et al. Late echocardiographic findings following childhood chemotherapy with normal serial cardiac monitoring. J Pediatr Hematol Oncol 18:72-75, 1996
17. Kalender S, Kavutcu M, Kalender Y, et al. Protective role of antioxidant vitamin E and catechin on doxorubicininduced cardiotoxicity in rats. Cancer Res Ther Control 11:175-182, 2001
18. Keefe DL. Anthracycline-induced cardiomyopathy. Semin Oncol 28(4 Suppl 12):2-7, 2001
19. Kremer LC, Bastiaansen BA, Offriga M, et al. In the first 24 hours after administration of chemotherapy and the detection of mycardial damage in children. Eur J Cancer 38:686-689, 2002
20. Kremer LCM, van Dalen EC, Offriga M, et al. Anthracyclin induced clinical heart failure in a cohort of 607 children: Long-term follow-up study. J Clin Oncol 19:191-196, 2001
21. Kremer LCM, van Dalen EC, Offriga M, et al. Frequency and risk factors of anthracycline-induced clinical heart failure in children: A systemetic review. Ann Oncol 13:503-512, 2002
22. Leandro J, Dyck J, Poppe D, et al: Cardiac dysfunction late after cardiotoxic therapy for childhood cancer. Am J Cardiol 74:1152-1166, 1994
23. Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302-314, 1973
24. Lemez P, Maresova J. Protective effects of cardioxane against anthracycline-induced cardiotoxicity in relapsed acute myeloid leukemia. Neoplasma 43:417-419, 1996
25. Lipschultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808-815, 1991
26. Lipschultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738-1743, 1995
27. Lipschultz SE, Sallan SE. Cardiovascular abnormalities in long-term survivors of childhood malignancy. J Clin Oncol 11:1199-1203, 1993
28. Lipschultz SE. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J Clin Oncol 14:328-331, 1996
29. Lipschultz SE, Colan SD. Cardivascular trials in longterm survivors of childhood cancer. J Clin Oncol 22:769- 773, 2004
30. Lipschultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicintreated children with acut lymphoblastic leukemia. N Engl J Med 351:245-153, 2004
31. Lipschultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin treated survivors of childhood cancer. J Clin Oncol 20:4517-4522, 2002
32. Lipschultz SE, Lipsitz SR, Sallan, SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acut lymphoblastic leukemia. J Clin Oncol 23:2629-2636, 2005
33. Lopez M, Vici P, Di Laura L, et al. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 16:86-92, 1998
34. Minotti G, Cairo G, Monti E. Role of iron in anthracycline cardiotoxicity: Tones for an old say. FASEB J 13:199-212, 1999
35. Minow RA, Benjamin RS, Lee ET, et al. Adriamycin cardiomyopathy - Risk factors. Cancer 39:1397-1402, 1977
36. Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol 25(Suppl 10):10-14, 1998
37. Perkins WE, Schroeder RL, Carrano RA, et al. Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig. Br J Cancer 46:662-667, 1982
38. Pihkala J, Saarinen UM, Lundstrom U, et al. Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer 32A:97-103, 1996
39. Rubio ME, Wiegmann A, Naeff MSJ, et al. ICRF-187 (Cardioxane) protection against doxorubicin induced cardiomyopathy in paediatric osteosarcoma patients. Proc Am Soc Clin Oncol 14:1403, 1995
40. Schuler D, Horvath E, Koós R, et al. Safety of dexrazoxane in children with ALL undergoing anthracycline therapy. Pediatr Hematol Oncol 14:93-94, 1997
41. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function to decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 22:820-828, 2004
42. Silber JH, Cnaan A, Clark BJ, et al. Design and baseline characteristic for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors. Am Heart J 142:577-585, 2001
43. Smith MA, Ungerleider RS, Horowitz ME, et al. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 83:1460-1470, 1991
44. Sparano JA, Speyer J, Gradishar WJ, et al. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. J Clin Oncol 17:880-886, 1999
45. Sparano JA. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicintaxane combinations. Semin Oncol 25(Suppl 10):66-71, 1998
46. Speyer JI, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117-127, 1992
47. Steinherz LJ, Steinherz PG, Tan CTC, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672-1677, 1991
48. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicincontaining therapy in advanced breast cancer. J Clin Oncol 15:1318-1322, 1997
49. Venturini M, Michelotti A, Del Mastro L, et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 14:3112-3120, 1996
50. Venturini M, Michelotti A, Del Mastro L, et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 14:3112-3120, 1996
51. Villani F, Galimberti M, Monti E, et al. Effect of ICRF- 187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat. Toxicol Appl Pharmacol 102:292-299, 1990
52. Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 14:362-372, 1996
53. Wexler LH. Ameliorating anthracycline cardiotoxicity in children with cancer: Clinical trials with dexrazoxane. Semin Oncol 25(Suppl 10):86-92, 1998
54. Yeung ST, Yoong C, Spink J, et al: Functional myocardial impairment in children treated with anthracycline for cancer. Lancet 337:816-818, 1991